Table 1.
ERE‐SNP (CYP2B6 rs16974799) Genotypes association to MMT dosing of cohort 1
| Genotype | ≤50 mg (n = 79) | 51~99 mg (n = 127) | ≥100 mg (n = 64) | P‐value | |
|---|---|---|---|---|---|
| CC | 41 (51.9%) | 83 (65.4%) | 48 (75.0%) | 0.0441* | |
| CT | 33 (41.8%) | 41 (32.3%) | 15 (23.4%) | ||
| TT | 5 (6.3%) | 3 (2.4%) | 1 (1.6%) | ||
| Dominant | CC+CT | 41 (51.9%) | 83 (65.4%) | 48 (75.0%) | 0.0148* |
| TT | 38 (48.2%) | 44 (34.7%) | 16 (25.0%) | ||
| Recessive | CT+TT | 74 (93.7%) | 124 (97.6%) | 63 (98.4%) | 0.2024 |
| CC | 5 (6.3%) | 3 (2.4%) | 1 (1.6%) | ||
pMax, Maximal MMT dose before enter this trial; SS, steady‐state MMT dose in this trial; Max, Maximal MMT dose during this trial; avg, average; S.D., standard deviation; [E2], 17β‐oestradiol; [P4], pregn‐4‐ene‐3,20‐dione (progesterone). *P < 0.05; **P < 0.01.